Lung Transplantation for Interstitial Lung DiseasesLung Transplantation for Interstitial Lung Diseases
Select patients with interstitial lung diseases and pulmonary hypertension may benefit from lung transplantation, even though the number of transplants performed is limited by the supply of donor organs. Which patients should be on the waiting list? Seminars in Respiratory and Critical Care Medicine
CONCLUSION: The diagnostics and treatment of CTD-ILD and PH in patients with an underlying autoimmune disease requires an interdisciplinary approach. The effectiveness of antifibrotic treatment needs to be evaluated in the future. PMID: 30006857 [PubMed - as supplied by publisher]
Repair of Hemi-Truncus with "Irreversible" Pulmonary Hypertension. Ann Thorac Surg. 2018 Jul 13;: Authors: Sha JM, Cao Y, Xu SS Abstract Anomalous origin of the pulmonary artery from the ascending aorta (AOPA) can lead to congestive heart failure in infancy and with advancing age many patients will develop severe pulmonary hypertension. Surgical intervention had high mortality/morbidity risk if this happens. Strategies to manage these patients seem only limited to heart-lung transplantation or lung transplantation. Here, we successfully carried out surgical intervention to in an adult patien...
Despite advances in targeted medical therapy, pulmonary arterial hypertension (PAH) remains a fatal disease because of progressive right ventricular dysfunction. For patients who are refractory to medical therapy, heart-lung and lung transplantation are important treatment options. Because of longer waiting time, surgical interventions including extracorporeal lung support and atrial septostomy can be used in PAH patients bridging to transplantation.
We examined safety and long-term outcomes of intravenous treprostinil administered via the implantable LENUS Pro ® pump in patients with severe pulmonary hypertension (PH).
AbstractA 27-year-old female patient had presented progressing exertional dyspnea due to pulmonary hypertension. Chest CT revealed diffusely spread patchy ground-glass opacities sparing subpleural parenchymal areas suggesting the diagnosis of pulmonary veno-occlusive disease (PVOD). Despite the diagnosis of PVOD, she was somehow managed by a repetitive escalation of the epoprostenol dose and oxygen supply during the 12-month waiting period until successful bilateral lung transplantation was performed. Pathology demonstrated capillary proliferation in alveolar septae with scarce lesions of narrowed and/or occluded postcapil...
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare but severe complication of acute pulmonary embolism leading to right heart failure and premature mortality. Its cumulative incidence ranges from 0.1 –9.1% within the first 2 years after symptomatic acute pulmonary embolism, although probably underestimated due to the lack of systematic follow-up and screening in clinical routine.1–3
Clinical Transplantation, EarlyView.
Chronic thromboembolic pulmonary hypertension (CTEPH) results from persistent pulmonary vascular obstructions, presumably due to inflammatory thrombosis. Because estimates of thrombus volume at diagnosis have no predictive value, we investigated the role of the thrombosis marker D-dimer and the inflammation marker C-reactive protein (CRP) for predicting outcomes in CTEPH.
We report a very rare case of pulmonary chromomycosis caused by Scedosporium prolificans that developed after lung transplantation and was successfully treated with endobronchial topical amphotericin B instillation. The subject was a woman in her 50s with a history of bilateral lobar lung transplantation from living donors for idiopathic pulmonary hypertension. Eight years after the lung transplantation, chest radiography X-ray and computed tomography showed an abnormal shadow in the right lung.
The pathobiology of chronic thromboembolic pulmonary hypertension (CTEPH) is poorly understood. Metabolic dysregulation is prominent in idiopathic pulmonary arterial hypertension (IPAH). Using an “omics” approach, we sought to determine the metabolic fingerprint of CTEPH patients compared to IPAH and healthy controls.